Test Price
2,800 AED✅ Home Collection Available
CFC1 Gene Heterotaxy, Visceral Type 2 Genetic Test in UAE
Executive Summary & Core Metrics
Diagnostic Performance: 99.9% sensitivity via ISO 15189 accredited NGS platform.
Sample Collection: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Post-Test Support: Telephonic clinical guidance for result interpretation by a DHA-licensed genetic specialist.
Insurance Verification: Direct billing support via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) test analyzes the CFC1 gene to detect pathogenic variants associated with Heterotaxy, visceral type 2 (HTX2), a disorder affecting left-right axis determination during embryonic development. The assay provides definitive molecular diagnosis for affected individuals, enables carrier testing for family members, and supports informed reproductive planning through comprehensive genetic counseling.
| Feature | DNA Labs UAE CFC1 Panel | Research-Only Exome Panel |
|---|---|---|
| Method & Coverage | Targeted NGS with full CFC1 coding region and splice-site coverage, validated for clinical use | Incidental finding from whole exome sequencing; often lacking depth for CFC1 |
| Turnaround Time | 3-4 Weeks | 6-8 Weeks |
| Clinical Review | Board-certified molecular geneticist report with pre/post counseling | Automated bioinformatics pipeline; no specialist oversight |
| Regulatory Compliance | UAE PDPL and DHA/MOHAP approved (License 1143) | May not meet UAE data protection standards |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“This genetic test for CFC1-related heterotaxy provides essential molecular confirmation, but results must be interpreted alongside detailed echocardiography and clinical assessment of visceral situs. Pre-test genetic counseling is critical to ensure families understand the variable expressivity and potential for associated cardiac anomalies. Treatment decisions, including surgical planning for congenital heart defects, should never rely solely on genetic findings.”
Exclusion Criteria & Emergency Guidance
- This test is not intended for acute diagnosis of cardiorespiratory distress or cyanotic spells.
- If the patient presents with severe respiratory compromise, tachypnea, or hemodynamic instability, proceed immediately to a pediatric cardiology emergency department.
- Non-invasive prenatal screening for heterotaxy syndromes is not clinically validated; this test utilizes postnatal whole blood or FTA card samples only.
Medical Warning: Never discontinue prescribed medications without consulting your treating physician.
Patient FAQ & Clinical Guidance
1. What does the CFC1 heterotaxy test diagnose and how long do results take?
This NGS-based test detects pathogenic mutations in the CFC1 gene that cause visceral heterotaxy type 2. It delivers a comprehensive molecular diagnostic report within 3 to 4 weeks from sample receipt.
2. How is the sample collected and can I use my health insurance?
A certified phlebotomist performs a paid home blood draw with temperature-controlled cold-chain transport. Insurance direct billing verification is available through WhatsApp at +971 54 548 8731.
3. Is pre-test genetic counseling required and who interprets the results?
Yes, mandatory pre-test genetic counseling includes family pedigree assessment and risk discussion. A DHA-licensed consultant medical geneticist provides a structured post-test result interpretation session.
UAE Regulatory & Data Privacy Adherence
Your data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All test results are handled through encrypted systems and shared only with authorized healthcare providers. Patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | CFC1 Gene Heterotaxy, Visceral Type 2 Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Whole Blood or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Q89.8 |
| LOINC Code | 48000-4 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians